62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring

Classification and Clinical Spectrum of Bipolar Disorders

Bipolar disorders are recurrent, life-shortening mood disorders characterized by pathological oscillations in mood, energy, psychomotor activity, and cognition. Correct classification is among the most consequential diagnostic tasks in family medicine, as misattributing bipolar disorder to unipolar major depression leads to inappropriate antidepressant monotherapy, precipitating acute manic exhaustion, cycle acceleration, and elevated suicide mortality.

                    THE BIPOLAR SPECTRUM: PHENOTYPIC SPECTRUM

   Disorder Category          Obligate DSM-5-TR Diagnostic Criteria & Episode Trajectory
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Bipolar I Disorder         • Requires at least ONE lifetime MANIC EPISODE (lasting >= 1 week or
                                requiring hospitalization).
                              • Major depressive episodes are typical throughout life but NOT required.
                              • Marked occupational/social impairment, psychotic features, or hospitalization.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Bipolar II Disorder        • Requires at least ONE HYPOMANIC EPISODE (lasting >= 4 consecutive days)
                                AND at least ONE MAJOR DEPRESSIVE EPISODE.
                              • Must NEVER have experienced a full manic episode.
                              • Observable change in functioning, but NO marked impairment, NO psychosis,
                                and NO psychiatric hospitalization.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Cyclothymic Disorder       • Persistent fluctuating mood disturbance for at least 2 YEARS in adults
                                (1 year in children/adolescents).
                              • Numerous periods of hypomanic symptoms (not meeting full criteria) and
                                depressive symptoms (not meeting major depressive episode criteria).
                              • Never symptom-free for > 2 consecutive months.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Mania versus Hypomania: The Cardinal Distinctions

The differentiation between full mania and hypomania is absolute and dictates diagnostic classification. While both share identical core symptom domains, they differ dramatically in duration, severity, and clinical complications:

                       MANIC EPISODE VS. HYPOMANIC EPISODE

   Diagnostic Feature         Manic Episode (Bipolar I)              Hypomanic Episode (Bipolar II)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Minimum Duration           At least 7 CONSECUTIVE DAYS            At least 4 CONSECUTIVE DAYS
                              (or any duration if hospitalized)      (observable by family/colleagues)
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Functional Impairment      MARKED IMPAIRMENT in social,           NO marked impairment in occupational
                              occupational, or interpersonal life    or social functioning
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Psychiatric Hospitalization Frequently required to prevent harm    NEVER REQUIRED (hospitalization
                              to self or others                      automatically classifies as Mania)
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Psychotic Features         May be present (delusions of grandeur, NEVER PRESENT (psychosis
                              paranoia, auditory hallucinations)     automatically classifies as Mania)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

The DIG FAST Mnemonic for Manic/Hypomanic Symptoms

Under DSM-5-TR, an episode requires a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased goal-directed activity or energy, accompanied by at least 3 symptoms (or 4 symptoms if the mood is only irritable) from the DIG FAST criteria:

• [D] Distractibility: Attention is easily drawn to unimportant, irrelevant external stimuli.
• [I] Indiscretion / Impulsivity: Excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g., unrestrained shopping sprees, sexual indiscretions, reckless driving, foolish financial investments).
• [G] Grandiosity: Inflated self-esteem or grandiosity, ranging from uncritical self-confidence to grandiose delusions of divine mission, special powers, or elite celebrity status.
• [F] Flight of Ideas: Subjective experience that thoughts are racing, accompanied by rapid, disjointed topic switching on speech examination.
• [A] Activity Increase: Substantial increase in goal-directed activity (socially, at work, at school, or sexually) or psychomotor agitation (aimless, non-goal-directed motor pacing).
• [S] Sleep Deficit: Decreased need for sleep (distinct from insomnia: the patient sleeps only 2 to 3 hours but awakens feeling completely rested, energized, and ready to conquer the day).
• [T] Talkativeness / Pressured Speech: Speech that is rapid, loud, intrusive, and exceedingly difficult to interrupt.

---

Screening Mandate: The Mood Disorder Questionnaire (MDQ)

Between 20% and 30% of patients presenting with major depressive episodes in primary care actually have an underlying bipolar diathesis. Patients rarely volunteer hypomanic symptoms during a depressive presentation because periods of hypomania are experienced as highly productive and ego-syntonic.

The Board-Style Pearl: The Peril of Antidepressant Monotherapy

Initiating antidepressant monotherapy (SSRIs, SNRIs, TCAs, or bupropion) in a patient with undiagnosed bipolar disorder without a concurrent mood-stabilizing agent carries devastating clinical consequences:

1. Precipitation of Acute Mania or Hypomania: Antidepressant-induced mood switching occurs in 15% to 40% of bipolar patients exposed to unipolar antidepressants.
2. Cycle Acceleration & Rapid Cycling: Antidepressants can destabilize mood rhythms, accelerating the patient into rapid cycling (defined as >= 4 distinct mood episodes within a 12-month period).
3. Induction of Mixed States: Produces a high-arousal state combining severe depressive dysphoria with manic psychomotor agitation and impulsivity—the clinical phenotype with the highest instantaneous risk of completed suicide.

Mandatory Clinical Practice: All primary care patients presenting with depression must be screened with the Mood Disorder Questionnaire (MDQ). An MDQ is positive if the patient endorses >= 7 of 13 lifetime hypomanic/manic symptoms occurring simultaneously, causing moderate to severe impairment. Any positive MDQ warrants mood stabilizer therapy or psychiatric referral, and strictly precludes unipolar antidepressant monotherapy.

---

Maintenance Pharmacotherapy: Lithium Carbonate (The Gold Standard)

Lithium carbonate is the premier gold-standard mood stabilizer for the long-term maintenance of Bipolar I Disorder. It demonstrates superior efficacy in preventing both manic and depressive recurrences and possesses unique neuroprotective and antisuicidal properties.

                  THE CARDINAL LIFE-SAVING PROPERTY OF LITHIUM

     Along with Clozapine, Lithium is one of only two psychiatric medications
       DEFINITIVELY PROVEN in randomized controlled trials and large cohort
          studies to substantially REDUCE THE RISK OF COMPLETED SUICIDE
                    and suicide attempts in bipolar patients.

Renal Handling and Pharmacokinetics of Lithium

Lithium is a monovalent cation with no plasma protein binding and zero hepatic metabolism. It is eliminated 100% unchanged by the kidneys:

• Proximal Tubule Reabsorption: Lithium is freely filtered at the glomerulus. In the proximal convoluted tubule, approximately 80% of filtered lithium is reabsorbed, utilizing the same paracellular pathways and sodium-hydrogen antiporters (NHE3) as sodium ions.
• The Sodium-Lithium Competition: The proximal tubule cannot distinguish between sodium and lithium. Consequently, any clinical condition or pharmacologic agent that induces hypovolemia, dehydration, or sodium depletion causes the proximal tubule to hyper-reabsorb sodium, simultaneously hyper-reabsorbing lithium, rapidly driving serum lithium concentrations into severe, life-threatening toxic ranges.

Therapeutic Window and Serum Trough Monitoring

Lithium has an extraordinarily narrow therapeutic index. Serum concentrations must be drawn precisely as a 12-hour trough level (exactly 12 hours after the evening dose, typically drawn at 8:00 AM after an 8:00 PM dose) at steady state (4 to 5 days after dose initiation or adjustment):

• Acute Manic Episode Target: 0.8 to 1.2 mEq/L
• Long-Term Maintenance Target: 0.6 to 1.0 mEq/L (In older adults or sensitive patients: 0.4 to 0.8 mEq/L)
• Toxicity Threshold: >= 1.5 mEq/L
• Severe/Life-Threatening Toxicity: > 2.0 to 2.5 mEq/L

                   LITHIUM LABORATORY MONITORING PROTOCOL

   Organ System / Parameter   Baseline Testing Requirements         Ongoing Routine Surveillance Schedule
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Serum Lithium Trough       Confirm steady state at 4-5 days      Every 3 to 6 months in stable patients;
   Level (12-hr trough)       after initial dose or titration       1 to 2 weeks after any dose adjustment
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Renal Function             Serum Creatinine, eGFR, BUN,          Every 6 months. Monitor for chronic
   (Tubulointerstitial risk)  and baseline Urinalysis               tubulointerstitial nephropathy and NDI
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Thyroid Function           Serum TSH and Free T4                 Every 6 to 12 months. Primary
   (Hypothyroidism / Goiter)                                        hypothyroidism develops in 10-20%
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Serum Calcium              Serum Calcium and Albumin             Every 12 months. Evaluates for lithium-
   (Hyperparathyroidism)                                            induced parathyroid hyperplasia / adenoma
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Cardiac Conduction         12-lead ECG in patients >= 40 years   Repeat periodically or if syncope occurs;
                              or with known cardiac disease         monitors sinus node dysfunction
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Pregnancy Status           Serum or urine hCG in all             Repeat immediately if menses delayed;
                              females of childbearing potential     screen for Ebstein anomaly in pregnancy
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Long-Term Organ Toxicities & Actionable Management

1. Thyroid Dysfunction (Hypothyroidism and Goiter):
   • Mechanism: Lithium concentrates in the thyroid follicular cells, inhibiting iodine uptake, iodotyrosine coupling, and thyroid hormone release.
   • Incidence: Primary hypothyroidism develops in 10% to 20% of patients, far more frequently in women.
   • Clinical Management Pearl: Do NOT discontinue lithium if mood is well controlled! Instead, continue lithium at the current therapeutic dose and initiate exogenous levothyroxine replacement therapy to normalize TSH.
2. Renal Dysfunction: Nephrogenic Diabetes Insipidus (NDI) & Chronic Kidney Disease:
   • Nephrogenic DI: Lithium enters principal cells of the medullary collecting duct via epithelial sodium channels (ENaC), inhibiting adenylate cyclase and downregulating aquaporin-2 water channels. Patients present with profound polyuria (>3 L/day) and polydipsia. Management: If lithium cannot be switched, Amiloride is the drug of choice because it selectively blocks ENaC, preventing further lithium accumulation inside collecting duct cells.
   • Chronic Tubulointerstitial Nephropathy: Long-term therapy (>10-20 years) can lead to irreversible interstitial fibrosis and tubular atrophy. If eGFR declines progressively below 30-45 mL/min or significant proteinuria develops, deliberate transition to an alternative mood stabilizer is warranted in consultation with nephrology.
3. Primary Hyperparathyroidism & Hypercalcemia:
   • Lithium alters the calcium-sensing receptor (CaSR) set-point in the parathyroid glands, stimulating parathyroid hormone (PTH) secretion and inducing multiglandular parathyroid hyperplasia or solitary adenomas. Check annual serum calcium.
4. Lithium in Pregnancy: The Real-World Risk of Ebstein Anomaly:
   • Historic teaching described massive risks of Ebstein anomaly (apical displacement of the tricuspid valve leaflets into the right ventricle, causing severe tricuspid regurgitation and 'atrialization' of the right ventricle).
   • Modern prospective registries demonstrate that the absolute risk is approximately 1 to 2 per 1,000 live births (compared to 1 per 20,000 in the general population). While this represents a 10- to 20-fold relative risk elevation, the absolute risk is far lower than historical estimates.
   • Perinatal Management: In women with severe, relapsing Bipolar I disorder, lithium may be maintained during pregnancy after rigorous informed consent. Perform a targeted fetal echocardiography and detailed anatomy scan at 18 to 22 weeks gestation. Lithium clearance increases by 30% to 50% during the second and third trimesters, requiring monthly trough monitoring, followed by an immediate dose reduction around delivery to prevent neonatal toxicity.

---

Lithium Toxicity: Stages, Precipitating Factors & Emergency Management

                   STAGING & PHENOTYPE OF LITHIUM TOXICITY

   Toxicity Stage           Serum Level                 Key Clinical Features & Neurological Findings
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Mild to Moderate         1.5 to 2.0 mEq/L            Coarse resting and intention tremor (vs. fine postural
   Toxicity                                             tremor at baseline), persistent nausea, vomiting, watery
                                                        diarrhea, muscular weakness, ataxia, and drowsiness.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Severe Toxicity          > 2.0 to 2.5 mEq/L          Gross confusion, disorientation, delirium, profound
                                                        cerebellar ataxia, hyperreflexia, diffuse myoclonus,
                                                        choreoathetosis, seizures, stupor, and acute oliguria.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Life-Threatening         > 3.5 to 4.0 mEq/L          Coma, intractable status epilepticus, cardiovascular
   Toxicity                                             collapse, multiorgan failure, permanent cerebellar injury
                                                        (SILENT syndrome), and death.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

The High-Yield Drug Interactions Triggering Toxicity

In board examinations and clinical practice, lithium toxicity is most commonly precipitated by the addition of common medications that alter renal hemodynamics or sodium handling:

                    PHARMACOLOGIC TRIGGERS OF LITHIUM TOXICITY

   Drug Class & Agents            Pathophysiologic Mechanism of Interaction     Relative Risk Level
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Thiazide Diuretics             Inhibit Na/Cl cotransporter in distal tubule. HIGHEST RISK DIURETIC:
   (HCTZ, Chlorthalidone)         Induces volume depletion, causing compensatory Increases serum lithium
                                  proximal tubule sodium/lithium reabsorption.  levels by 30% to 50%!
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   NSAIDs                         Inhibit renal prostaglandin synthesis,        DANGEROUS COMBINATION:
   (Ibuprofen, Naproxen,          blunting renal vasodilatory tone. Decreases   Increases serum lithium
   Celecoxib, Indomethacin)       renal blood flow and GFR, reducing excretion. levels by 25% to 40%!
                                  (Aspirin & Acetaminophen do not affect GFR).
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   ACE Inhibitors & ARBs          Dilate efferent arterioles, reducing intra-   GRADUAL TOXICITY:
   (Lisinopril, Losartan)         glomerular filtration pressure and GFR.       Causes insidious lithium
                                                                                accumulation over 1-3 weeks.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Loop Diuretics (Furosemide)    Induce volume contraction; less proximal      Moderate risk; monitor levels.
   Volume Loss / Dehydration      Gastroenteritis, febrile sweating, sauna.     High risk; triggers acute toxicity.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Emergency Management Algorithm for Lithium Toxicity

1. Immediate Cessation: Discontinue lithium immediately.
2. Stat Diagnostic Panel: Obtain serum lithium level, comprehensive metabolic panel (BUN, creatinine, electrolytes), and a 12-lead ECG.
3. Isotonic Normal Saline Hydration: Administer IV 0.9% Normal Saline at 150 to 200 mL/hr. Saline re-expands intravascular volume, restores renal perfusion, and provides sodium ions to the proximal tubule, competitively promoting urinary excretion of lithium.
4. Activated Charcoal is Ineffective: Activated charcoal DOES NOT bind monovalent cations like lithium and should never be administered for pure lithium ingestions.
5. Emergent Hemodialysis: Hemodialysis is the definitive, life-saving modality for severe lithium intoxication.
   • Absolute Indications for Hemodialysis:
     • Serum lithium level > 4.0 mEq/L, regardless of the patient's clinical symptoms.
     • Serum lithium level > 2.5 mEq/L in the presence of severe neurological manifestations (seizures, coma, delirium, myoclonus) or hemodynamic instability.
     • Serum lithium level > 2.5 mEq/L in patients with acute renal failure, chronic end-stage renal disease, or severe heart failure unable to tolerate vigorous saline hydration.
     • Patients whose lithium levels rise or fail to decline despite aggressive IV saline hydration.
   • Note on Dialysis Rebound: Lithium equilibrates slowly between intracellular and extracellular compartments. Serum lithium levels frequently rebound 6 to 12 hours after hemodialysis as intracellular lithium shifts into the vascular space, frequently necessitating a second dialysis session.

---

Alternative Mood Stabilizers & Second-Generation Antipsychotics

            ALTERNATIVE MAINTENANCE AGENTS FOR BIPOLAR DISORDER

   Medication     Target Levels & Monitoring       Clinical Niche & Efficacy    Black Box Warnings & Critical Risks
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Divalproex     Trough: 50-125 mcg/mL.           First-line for acute mania,  • HEPATOTOXICITY (microvesicular).
   Sodium /       Monitor: CBC (platelets),        mixed features, and rapid    • PANCREATITIS (hemorrhagic).
   Valproate      LFTs, lipase/amylase, weight.    cycling presentations.       • EXTREME TERATOGENICITY:
                                                                                  Neural tube defects (spina
                                                                                  bifida), 8-10 pt IQ drop!
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Lamotrigine    No therapeutic drug level.       First-line maintenance for   • STEVENS-JOHNSON SYNDROME (SJS)
   (Lamictal)     Strict slow titration: start     BIPOLAR DEPRESSION.          and Toxic Epidermal Necrolysis.
                  25 mg daily; slow escalation.    Ineffective for acute mania. • Valproate doubles half-life;
                                                                                  must cut dose by 50%!
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Quetiapine     Dose: 300 mg daily at bedtime.   FDA-approved monotherapy     Metabolic syndrome: weight gain,
   (Seroquel)     Monitor: fasting glucose, lipids, for acute bipolar depression  hypertriglyceridemia, diabetes;
                  BMI, annual AIMS exam.           and maintenance.             sedation and orthostasis.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Lurasidone     Dose: 20-80 mg daily with food   First-line for acute bipolar Minimal metabolic weight gain;
   (Latuda)       (>=350 calories). Monitor lipids, depression; pregnancy       must take with >=350 kcal meal;
                  glucose, and AIMS exam.          favorable.                   akathisia and EPS risk.
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Cariprazine    Dose: 1.5-3 mg daily.            D3/D2 partial agonist;       Akathisia, restlessness, EPS;
   (Vraylar)      Monitor lipids, glucose, AIMS.   bipolar depression & mania.  long half-life (active weeks).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Divalproex Sodium: Teratogenicity & Surveillance Pearls

Divalproex sodium (valproate) is highly effective for euphoric and dysphoric mania, mixed episodes, and rapid cycling. However, its use is heavily constrained by serious toxicities:

• Dose-Dependent Thrombocytopenia: Platelet counts must be checked at baseline and periodically; counts <100,000/mcL require dose reduction or discontinuation.
• Black Box Hepatotoxicity & Pancreatitis: Monitor transaminases and abdominal pain symptoms. Fatal hemorrhagic pancreatitis can develop unpredictably at any time during therapy.
• Extreme Teratogenicity: First-trimester valproate exposure carries a 1% to 2% risk of neural tube defects (lumbar spina bifida), craniofacial defects, cardiovascular anomalies, and severe neurodevelopmental harm (producing an average 8- to 10-point reduction in childhood IQ and high rates of autism spectrum disorder). Valproate is strictly contraindicated in females of childbearing potential unless all alternative therapies have failed and two forms of reliable contraception are documented.

Lamotrigine: Slow Titration and Stevens-Johnson Syndrome

Lamotrigine is the premier maintenance mood stabilizer specifically for preventing depressive recurrences in Bipolar I and Bipolar II disorder (it lacks efficacy for acute mania).

• Black Box Warning for SJS/TEN: The risk of life-threatening Stevens-Johnson syndrome is directly tied to the speed of initial dose titration. Titration must follow a rigid protocol: 25 mg daily for Weeks 1 and 2, then 50 mg daily for Weeks 3 and 4, then 100 mg daily for Week 5, reaching target 200 mg daily at Week 6.
• The Rule of Discontinuation: If a patient misses lamotrigine for more than 5 half-lives (approximately 5 days), tolerance to the titration is lost. The clinician MUST restart the titration from 25 mg daily rather than resuming the full maintenance dose.
• The Critical Valproate Drug Interaction: Valproate potent inhibits lamotrigine glucuronidation, more than doubling the elimination half-life of lamotrigine (from ~25 hours to ~60 hours). When adding lamotrigine to valproate, the lamotrigine starting dose MUST BE REDUCED BY AT LEAST 50% (starting 25 mg every other day) to avoid triggering SJS. Conversely, enzyme inducers (carbamazepine, phenytoin, and estrogen-containing oral contraceptives) double lamotrigine clearance, requiring higher maintenance doses.

Second-Generation Antipsychotics (SGAs) & Metabolic Surveillance

Second-generation antipsychotics play an indispensable role in bipolar management:

• Bipolar Depression: Monotherapy with Quetiapine, Lurasidone (taken with >= 350 kcal meal), Cariprazine, or Olanzapine-Fluoxetine combination (OFC) are FDA-approved first-line treatments.
• Acute Mania & Maintenance: Aripiprazole, Risperidone, Olanzapine, and Ziprasidone are robust anti-manic agents.
• Mandatory Metabolic Surveillance (ADA/APA Consensus Protocol):
  • Fasting Plasma Glucose / HbA1c: Baseline, 3 months, then annually.
  • Fasting Lipid Profile: Baseline, 3 months, then annually.
  • Body Weight and BMI: Baseline, 4 weeks, 8 weeks, 12 weeks, then quarterly.
  • Blood Pressure & Waist Circumference: Baseline and annually.
  • Abnormal Involuntary Movement Scale (AIMS): Every 6 to 12 months to detect early tardive dyskinesia (involuntary choreoathetoid movements of the tongue, face, or extremities).